Mizuho Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs (NASDAQ:ESTA) had its price target raised by research analysts at Mizuho from $90.00 to $100.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price target would suggest a potential upside of 29.62% from the stock’s previous close.

ESTA has been the topic of a number of other reports. Needham & Company LLC upped their price target on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Tuesday. Canaccord Genuity Group upped their target price on Establishment Labs from $72.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. JPMorgan Chase & Co. increased their target price on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Stephens boosted their price target on shares of Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, BTIG Research upped their price objective on shares of Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.00.

Establishment Labs Stock Down 1.5%

Establishment Labs stock opened at $77.15 on Wednesday. The company has a market capitalization of $2.24 billion, a PE ratio of -44.34 and a beta of 0.99. Establishment Labs has a 12-month low of $26.56 and a 12-month high of $83.31. The firm’s fifty day moving average is $71.21 and its 200 day moving average is $58.00. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 197.22%. The business had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. During the same period last year, the company posted ($1.19) earnings per share. The business’s quarterly revenue was up 45.2% on a year-over-year basis. As a group, sell-side analysts predict that Establishment Labs will post -2.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Establishment Labs

Several institutional investors have recently modified their holdings of ESTA. Simplify Asset Management Inc. purchased a new position in shares of Establishment Labs in the 3rd quarter worth about $1,555,000. Tejara Capital Ltd raised its position in Establishment Labs by 31.2% in the third quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock worth $4,201,000 after acquiring an additional 24,386 shares during the period. Woodson Capital Management LP boosted its stake in Establishment Labs by 113.3% in the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock valued at $19,675,000 after acquiring an additional 255,000 shares during the last quarter. Affinity Asset Advisors LLC grew its position in shares of Establishment Labs by 19.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 334,863 shares of the company’s stock valued at $14,302,000 after acquiring an additional 54,863 shares during the period. Finally, Hood River Capital Management LLC grew its position in shares of Establishment Labs by 138.2% during the 2nd quarter. Hood River Capital Management LLC now owns 53,124 shares of the company’s stock valued at $2,269,000 after acquiring an additional 30,825 shares during the period. 72.91% of the stock is owned by institutional investors.

Trending Headlines about Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Multiple brokerages raised price targets and kept bullish ratings — Canaccord raised its target to $90 and kept a Buy rating, Stephens raised to $90 with an Overweight, Mizuho lifted to $100 with an Outperform, and BTIG moved to $88 with a Buy — reinforcing analyst conviction and upside. Analyst Price Target Raises (Benzinga)
• Positive Sentiment: Q4 2025 results beat expectations: revenue (~$64.6M) and EPS beat consensus, with year‑over‑year revenue growth (~45%) — results and commentary underpin the recent analyst upgrades. Q4 2025 Earnings Call Summary (Yahoo)
• Positive Sentiment: Management provided 2026 guidance targeting at least 25% revenue growth and emphasized expansion of minimally invasive platforms — a clear growth thesis that supports higher valuation if execution continues. 2026 Revenue Guidance & Platform Expansion (MSN)
• Neutral Sentiment: Company announced a leadership transition framed as supporting the next phase of growth — this is management-level news to monitor for execution risk but not an immediate negative. Leadership Transition (Yahoo)
• Neutral Sentiment: Analyst note roundup summarizes 11 analysts’ views — useful context on street sentiment and target dispersion but adds no single new catalyst. Analyst Roundup: 11 Analysts (Benzinga)
• Negative Sentiment: Market reaction: shares are trading lower today despite the earnings beat, guidance and several price‑target raises — suggests some profit‑taking or skepticism about margins/near‑term profitability. Market Reaction

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.